Acadia Pharmaceuticals Reports P-III Study (LAVENDER) Results of Daybue (trofinetide) for the Treatment of Rett Syndrome
- The P-III study results published in Nature Medicine evaluating Daybue vs PBO in 187 girls and young women aged 5-20yrs.
- The results showed an improvement over PBO on co-primary efficacy EPs, mean change from baseline to 12wk. in RSBQ total score was −5.1 vs −1.7, and LSM changes from baseline to 12wk. in the RSBQ total score, based on the MMRM analysis was −4.9 vs −1.7, change from baseline for all RSBQ domain subscores were numerically in Daybue's favour
- Mean CGI-I scores @12wk. (3.5 vs 3.8), MMRM analysis showed an improvement with an LSM difference of −0.3, a similar benefit was observed in the subgroup analysis irrespective of age, baseline RSBQ severity & category of documented disease-causing MECP2 mutation severity
Ref: BusinessWire | Image: Acadia
Related News:- Acadia Pharmaceuticals Launches Daybue (trofinetide) for the Treatment of Rett Syndrome in the US
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at firstname.lastname@example.org
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.